Adocia (ADOC) Investor presentation summary

Market context and medical need

• Diabetes and obesity affect over 2.4 billion people globally, representing major metabolic pandemics.

• The combined diabetes and obesity therapeutics market is projected to reach $100 billion by 2030.

• Innovative peptide delivery solutions are positioned to address significant unmet medical needs.

Technology platforms and product pipeline

• Proprietary platforms include BioChaperoneⓇ (peptide co-formulation), AdOralⓇ (oral peptide delivery), AdoGel® (extended injectable efficacy), and AdoShellⓇ (cell therapy without immunosuppression).

• BioChaperoneⓇ enables stable co-formulation of peptides such as CagriSema, with clinical and industrial scalability demonstrated.

• AdoShellⓇ offers a unique cell therapy approach, protecting cells and avoiding immunosuppressants.

Strategic partnerships and development milestones

• Strong partnership with Tonghua Dongbao in China for BC Lispro, with Phase 3 completion and $10 million milestone expected in December 2024.

• Global licensing discussions ongoing for M1Pram with Sanofi and for BioChaperone® Amyline-GLP-1 combinations.

• Preclinical proof of concept and first-in-human studies planned for AdoShellⓇ technology.